TACSTD2 and neoplasm: Consistent with this view, TROP2-positive tumor cells may be killed by the intracellular uptake of DXd whereas adjacent cells (i.e., TROP2-negative tumor and/or endothelial/stromal cells) may be damaged by its extracellular release.